NRG research plays a vital role in advancing and preserving Dutch expertise in nuclear technology and safety. As a global leader in medical isotope production, it also serves as a national authority on comprehensive radiation protection standards in the Netherlands. 

NRG operates the High Flux Reactor (HFR) in Petten, Noord-Holland, and is currently advancing the PALLAS project, a state-of-the-art isotope production facility designed to succeed the HFR. With a dedicated team of 700 skilled professionals, NRG applies extensive knowledge to support its partners in energy, industry, science, government, and healthcare. 

As part of the SANE project, NRG is actively involved in various packages, with significant contributions to WP2 and WP4. In WP2, NRG focuses on probabilistic safety considerations, severe accidents, and radiological consequences, as well as the applicability of deterministic safety assessment tools. In WP4, NRG addresses radiological risks, risk communication, and stakeholder perceptions regarding the deployment of novel nuclear applications. 

Additionally, NRG leads WP3, which evaluates non-electric applications of nuclear reactors. This role includes conducting performance and safety assessments for systems coupled with reactors, such as district heating, hydrogen production, industrial heat, and agricultural applications.